Skip to main content
Journal cover image

Primary Spinal Cord Astrocytomas: Two-Center Clinical Experience of Low- and High-Grade Lesions.

Publication ,  Journal Article
Snyder, MH; Yu-Der Wang, A; Ampie, L; Sarathy, D; Chatrath, A; Asthagiri, AR; Shaffrey, CI; Smith, JS; Shaffrey, ME; Yen, C-P; Buchholz, AL ...
Published in: World Neurosurg
November 2022

OBJECTIVE: Primary spinal cord astrocytomas are rare, fatal, and poorly studied. METHODS: This study included a 2-center, retrospective analysis of primary spinal cord astrocytoma patients from 1997 to 2020. Patients with drop metastases or without at least one follow-up were excluded. RESULTS: Seven World Health Organization grade I, 6 grade II, 7 grade III, and 4 grade IV astrocytoma patients were included. Older patients had higher grades (median 20 years in grade I vs. 36.5 in grade IV). The median follow-up was 15 months. Thirteen patients were discharged to rehabilitation. Eight patients demonstrated radiographic progression. Adjuvant therapy was utilized more in higher grades (5 of 13 grades III vs. all 11 grades IIIIV). Six patients died (1 death in grades III vs. 5 in grades IIIIV). Ten patients had worsened symptoms at the last follow-up. The median progression-free survival in grade I, II, III, and IV tumors was 116, 36, 8, and 8.5 months, respectively. The median overall survival in grade I, II, III, and IV tumors was 142, 69, 19, and 12 months, respectively. Thrombotic complications occurred in 2 patients, one with isocitrate dehydrogenasewild type glioblastoma. CONCLUSIONS: Outcomes worsen with higher grades and lead to difficult postoperative periods. Clinicians should be vigilant for thromboembolic complications. Further research is needed to understand these rare tumors.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

World Neurosurg

DOI

EISSN

1878-8769

Publication Date

November 2022

Volume

167

Start / End Page

e1006 / e1016

Location

United States

Related Subject Headings

  • Spinal Cord Neoplasms
  • Retrospective Studies
  • Humans
  • Combined Modality Therapy
  • Astrocytoma
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Snyder, M. H., Yu-Der Wang, A., Ampie, L., Sarathy, D., Chatrath, A., Asthagiri, A. R., … Heilman, C. B. (2022). Primary Spinal Cord Astrocytomas: Two-Center Clinical Experience of Low- and High-Grade Lesions. World Neurosurg, 167, e1006–e1016. https://doi.org/10.1016/j.wneu.2022.08.130
Snyder, M Harrison, Andy Yu-Der Wang, Leonel Ampie, Danyas Sarathy, Ajay Chatrath, Ashok R. Asthagiri, Christopher I. Shaffrey, et al. “Primary Spinal Cord Astrocytomas: Two-Center Clinical Experience of Low- and High-Grade Lesions.World Neurosurg 167 (November 2022): e1006–16. https://doi.org/10.1016/j.wneu.2022.08.130.
Snyder MH, Yu-Der Wang A, Ampie L, Sarathy D, Chatrath A, Asthagiri AR, et al. Primary Spinal Cord Astrocytomas: Two-Center Clinical Experience of Low- and High-Grade Lesions. World Neurosurg. 2022 Nov;167:e1006–16.
Snyder, M. Harrison, et al. “Primary Spinal Cord Astrocytomas: Two-Center Clinical Experience of Low- and High-Grade Lesions.World Neurosurg, vol. 167, Nov. 2022, pp. e1006–16. Pubmed, doi:10.1016/j.wneu.2022.08.130.
Snyder MH, Yu-Der Wang A, Ampie L, Sarathy D, Chatrath A, Asthagiri AR, Shaffrey CI, Smith JS, Shaffrey ME, Yen C-P, Buchholz AL, Syed HR, Kryzanski J, Wu JK, Heilman CB. Primary Spinal Cord Astrocytomas: Two-Center Clinical Experience of Low- and High-Grade Lesions. World Neurosurg. 2022 Nov;167:e1006–e1016.
Journal cover image

Published In

World Neurosurg

DOI

EISSN

1878-8769

Publication Date

November 2022

Volume

167

Start / End Page

e1006 / e1016

Location

United States

Related Subject Headings

  • Spinal Cord Neoplasms
  • Retrospective Studies
  • Humans
  • Combined Modality Therapy
  • Astrocytoma
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences